GLP-1s and Muscle Loss

The short answer: yes, but only because it is causing weight loss. Part of what comes off is lean tissue rather than fat, a substantial part of that lean tissue is muscle, and that happens with any weight loss however you do it. What is different here is the total: these medications take off far more weight than most people manage otherwise and keep going for a year or more, so more muscle goes with it. Most of what decides how much you keep is what you do while the weight is coming off.

What happens to your muscle on a GLP-1?

Losing weight means running an energy shortfall, and your body covers part of that shortfall from tissue other than fat. That happens whether the shortfall comes from eating less, from surgery, or from a medication that makes you less hungry. Nothing about these drugs singles out muscle. How GLP-1s work covers why the shortfall happens in the first place.

What gets measured, though, is a different thing from what gets lost. Almost everything we know here comes from a DXA scan. It is a low-dose X-ray that takes a few minutes and sorts your body into three buckets: fat, bone, and everything else. That third bucket is called lean mass, and it is not the same thing as muscle. It also holds your organs, your gut, your skin, and the water your tissues carry.

So a lean mass figure is not a muscle figure. It is not a number to wave away either. A review that gathered up the studies measuring both found skeletal muscle made up between 55% and every last percent of the lean tissue lost, and in one study more than all of it. Where lean mass counts other tissue, it is counting less of it than you might hope.

That range needs a caveat, and it is a real one. The review was published in 2019, and it pooled 44 studies across two different classes of diabetes drug: 17 on GLP-1 drugs and 27 on a separate class that works differently. The seven studies that produced the 55% to 100% range are not identified by class anywhere in the paper, so nobody can say whether they were the GLP-1 studies, the others, or a mix. It matters which, because the other class makes you lose water, and water shows up on a scan as lean tissue. Only one of the 17 GLP-1 studies used semaglutide, at a diabetes dose.

So the honest position is that this is the only measurement of its kind anyone has made, it points at muscle making up a large share of the lean tissue lost during this sort of weight loss, and it has never been repeated on the obesity doses most people take now. We are not going to tell you the lean mass on your scan is mostly water and organ tissue, because nothing shows that. We are also not going to attach a percentage to it that was measured somewhere else.

How much muscle do you actually lose?

For every four pounds that come off, roughly three are fat and one is lean tissue. Most of that one pound is muscle. And that split is close to what happens to anyone losing weight, by any method.

The clearest picture comes from a trial of tirzepatide, sold as Mounjaro and Zepbound, that scanned 160 people over about seventeen months. They lost around a fifth of their body weight, and it came off in that same three-to-one proportion. The people in the same trial taking a placebo lost theirs in the same proportions.

The three-to-one split is a rule of thumb rather than a law. One review of it found the rule has little mechanism behind it, and the real proportion shifts with how much body fat you start with, your age, your sex, how large the shortfall is, and whether you exercise. Treat three-to-one as the neighborhood, not the number. Our free muscle-loss risk estimator walks through those same factors.

A 2026 review that compared methods side by side put it plainly: lean tissue losses look broadly similar whether weight comes off through eating differently, through one of these medications, or through surgery.

What is different is how much. These medications take off far more weight than most people achieve otherwise, and they do it for a year or more without the usual plateau. The proportions stay roughly the same, so the amount of lean tissue lost scales with the amount of weight lost. A quarter of a lot is more than a quarter of a little. That is the honest reason to take this seriously, and it is a better reason than speed: week to week, weight comes off on these drugs at a pace most diet advice would call moderate.

If you have run into a scarier number. A figure of around 40% circulates widely. It comes from dividing one result of a large semaglutide trial by another, so it is a calculation rather than something a scan measured. The body scan substudy from that same trial read more calmly: lean mass fell, but as a share of body weight it actually went up, because fat came off faster than everything else.

Is this a reason not to take a GLP-1? We do not think so. Nothing here says these drugs do something unusual to muscle. It says that losing weight costs lean tissue no matter how you do it, that these medications take off a lot of weight, and that most of how much muscle you keep is under your control.

How do you protect your muscle on a GLP-1?

Strength training. Protein supports it, and the order is not interchangeable.

That ordering is the opposite of how most advice is written. Protein is a product and strength training is not. The clinical consensus runs the other way round: eating more protein on its own is probably not enough to protect muscle without structured strength work alongside it.

Across six trials of older adults eating less to lose weight, those who also lifted kept almost all of the lean tissue the others lost. Their fat loss did not suffer for it. They lost the same amount of weight and arrived with more of their body intact.

None of those people were on a GLP-1. The evidence that strength training protects muscle during weight loss is strong, and it comes from people dieting and from older adults, not from GLP-1 trials. Nobody has run that trial at scale yet. We think the finding carries over, because the reason it works has nothing to do with which drug you take. But we are telling you it is an extrapolation, because everyone else states it as settled.

A larger review sorted through the options and found the same pattern. Lifting, or lifting plus cardio, protected muscle better than cardio on its own. Only the combination actually built muscle. Walking is a good place to start, but it is not the only answer to this particular problem.

Clinical guidelines recommend strength training at least three times a week, plus at least 150 minutes a week of moderate activity. That is a consensus recommendation rather than a tested dose, so treat it as a target to move toward.

On protein. The usual advice is 1.2 to 1.6 grams per kilogram of body weight a day, which is about 0.55 to 0.7 grams per pound, or roughly 80 to 120 grams. Three things about it rarely get mentioned.

The first is who paid for the research. Much of the work behind those targets was funded by companies that sell protein, including a meal replacement company and a summit backed by the meat, dairy and egg industries. The numbers may well be right. The enthusiasm is sponsored. A 2026 review with no manufacturer funding lands a little lower, at 1 to 1.5 grams per kilogram (0.45 to 0.7 per pound), and higher for people over about 65.

The second is which body weight you use. Your protein need tracks your lean tissue, not your fat, so applying the target to your current weight overshoots if you are carrying extra. Using an adjusted weight instead can change the answer by 50 grams a day or more. If a number looks impossible to eat, that is often why. Our protein calculator uses the adjusted figure.

The third is that this target is not for everyone. Every study behind it was run in people with normal kidney function. If you have chronic kidney disease, how much protein you should eat is a question for the clinician managing it, and a higher target is not automatically the right answer. Age moves the number too: the independent review puts people over about 65 higher within the range.

More is not better past that point. Eating well beyond what your muscles can use adds nothing.

One practical problem here is specific to these drugs. The medication works by making you less hungry, so eating 100 grams of protein a day is harder than it sounds, especially in the first weeks and after each dose increase. Nausea makes it harder still. Our guide to managing side effects covers how to get through that stretch, and we have ranked protein powders for the days eating is hard.

What about creatine? It is the supplement people ask about most, and it is about as safe as supplements get. More than a thousand studies have found no consistent evidence of harm in healthy people, including no sign of kidney damage. Taken alongside strength training it does add strength, by a small but fairly consistent amount.

The evidence thins out when you ask who it helps most. Several reviews published in the last year could not agree on whether creatine helps older adults more or less than younger ones, and most of the people studied were men. On grip strength, which is one of the cheapest ways to track your own muscle, there was no clear effect at all.

We couldn’t find any trials that tested creatine in people losing weight, let alone anyone on a GLP-1. The first trial to try started recruiting in May 2026. It is measuring how many times people on a GLP-1 can stand up from a chair.

One note on bone. Bone density falls during weight loss too, and it gets discussed far less. Exercise is the best supported lever for protecting both. Be aware of how thin the direct evidence is: one trial has tested exercise alongside a GLP-1 and measured bone, and it used liraglutide rather than semaglutide or tirzepatide. It is still a good reason to start lifting even if muscle is not what worries you.

How can you tell if you are losing muscle?

Track what your muscles can do, not what a scan says they weigh. Most of the tests clinicians use for this are free.

The standard advice is to get a DXA scan. It is a useful test, but one scan on its own tells you little. What matters is the change between two of them, and that is the part most people never pay for.

Clinicians who follow this properly do not rely on scans alone. They also measure what your muscles can do, using four tests you can run at home for nothing:

1. Grip strength. How hard you can squeeze. Cheap hand dynamometers exist, or use any object you can grip and hold, and time it.
2. Walking speed. How long it takes you to walk a short measured distance, four to six metres.
3. Sit-to-stand. How many times you can stand up from a chair and sit back down in a row, without using your hands.
4. Six-minute walk. How far you get in six minutes at a comfortable pace.

The catch is that these are comparisons, not pass marks. A grip measurement in your first week is what makes the same measurement at month six mean anything. If you are about to start, this belongs on the list of things to sort out early, alongside everything else in starting a GLP-1. If you do get a scan as well, our lean body mass calculator puts the number in context.

There is reason to expect those numbers to hold up. In a real-world group of 106 people taking semaglutide, the drug in Ozempic and Wegovy, for a year, grip strength went up by 10 lb (4.5 kg), and the share who met the criteria for low muscle alongside higher weight fell from 49% to 33%. That study had no comparison group and ran at a single center, so it is a hopeful signal rather than proof.

There is a ceiling on all of this. No randomized trial has shown that these drugs increase measured strength. Strength looks preserved, and function looks steady or slightly better.

What it looks like when it goes well: in a series of three patients who trained three to five days a week and ate plenty of protein, two of the three gained lean tissue while losing between 13% and 33% of their body weight. Three people cannot tell you what is typical. They can tell you it is possible.

The thing to raise with a doctor is not a number on a scale. It is strength or walking speed getting worse rather than better. What you are aiming for has a name, body recomposition: less fat, the same muscle or more.

Is there a drug that prevents muscle loss?

Probably, eventually. Several are in trials. None is available, and none of them changes what helps you this week.

The furthest along pairs a GLP-1 with a second drug that blocks one of the body’s own brakes on muscle growth. In a trial of about 500 people, adding it cut lean tissue loss to a fraction of what the GLP-1 caused alone, and pushed the share of lost weight that was fat from around three quarters to more than nine tenths.

Keep it in perspective. This was a mid-stage trial of a drip given at the clinic every few months, and the drug is not approved for anything. It also reported lean mass on a scan rather than strength, and preserving a number on a scan is not the same as being stronger. Others of its kind are further behind.

The two things that help most are still strength training and enough protein, and both are available today.

What do we still not know about GLP-1s and muscle?

Quite a lot. Five gaps matter most.

Whether the drug itself does anything extra to lean mass. To answer that properly you would randomize people to the same calorie deficit with and without a GLP-1 and compare them. In humans, nobody has.

Whether muscle comes back if you stop. Weight regain after stopping is well documented. What happens to body composition across repeated cycles of losing and regaining is not, and researchers list it as an open question rather than a settled one.

What happens after two years. Almost all of the body composition data runs 68 to 72 weeks. Year three and year five have not been measured.

Whether the training evidence holds in people on these drugs. The trials showing that lifting protects muscle during weight loss were run in people dieting and in older adults. Nobody has repeated them in people taking a GLP-1. We expect the finding carries over, because the reason lifting works has nothing to do with which drug you take.

Whether the two main drugs differ. One 2026 analysis of routine care reported more lean mass loss on tirzepatide than on semaglutide. It has not been peer reviewed and it did not randomize anyone, so it cannot outweigh the randomized trials. We are telling you it exists because you may run into it.

Sources and review

How much you lose, and how much of it is muscle

• Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019;34(3):247. doi:10.3803/enm.2019.34.3.247. Full text
• Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275. Full text
• Wilding JPH, Batterham RL, Calanna S, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. J Endocr Soc. 2021;5(Supplement_1):A16-A17. doi:10.1210/jendso/bvab048.030. Full text
• Tinsley GM, Heymsfield SB. Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society. 2024;8(11). doi:10.1210/jendso/bvae164. Full text
• Heymsfield SB, Gonzalez MCC, Shen W, Redman L, Thomas D. Weight loss composition is one‐fourth fat‐free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15(4):310-321. doi:10.1111/obr.12143. Full text
• Fogarasi A, Gonzalez K, Dalamaga M, Magkos F. The Impact of the Rate of Weight Loss on Body Composition and Metabolism. Curr Obes Rep. 2022;11(2):33-44. doi:10.1007/s13679-022-00470-4. Full text
• De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin‐based therapies. Eur J Clin Invest. 2026;56(1). doi:10.1111/eci.70155. Full text
• Langer HT, Gilmore NK, Hayden CMT, et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Rep Med. 2026;7(3):102665. doi:10.1016/j.xcrm.2026.102665. Full text

What protects muscle: training

• Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018;10(4):423. doi:10.3390/nu10040423. Full text
• Eglseer D, Traxler M, Embacher S, et al. Nutrition and Exercise Interventions to Improve Body Composition for Persons with Overweight or Obesity Near Retirement Age: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2023;14(3):516-538. doi:10.1016/j.advnut.2023.04.001. Full text
• Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Netw Open. 2024;7(6):e2416775. doi:10.1001/jamanetworkopen.2024.16775. Full text
• Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023. Full text

What protects muscle: protein

• Grosicki GJ, Dhurandhar NV, Unick JL, et al. Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications. Curr Dev Nutr. 2024;8(11):104486. doi:10.1016/j.cdnut.2024.104486. Full text
• Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S. doi:10.3945/ajcn.114.084038. Full text
• Volek JS, Kackley ML, Buga A. Nutritional Considerations During Major Weight Loss Therapy: Focus on Optimal Protein and a Low-Carbohydrate Dietary Pattern. Curr Nutr Rep. 2024;13(3):422-443. doi:10.1007/s13668-024-00548-6. Full text
• Charidemou E, Ashmore T, Li X, et al. A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans. JCI Insight. 2019;4(12). doi:10.1172/jci.insight.124819. Full text

Creatine

• Zhang H, Lan T, Yan X, Gu H, Li Y, He E. Effects of creatine supplementation on muscle strength gains—a meta-analysis and systematic review. PeerJ. 2025;13:e20380. doi:10.7717/peerj.20380. Full text
• Kazeminasab F, Kerchi AB, Sharafifard F, et al. The Effects of Creatine Supplementation on Upper- and Lower-Body Strength and Power: A Systematic Review and Meta-Analysis. Nutrients. 2025;17(17):2748. doi:10.3390/nu17172748. Full text
• Sharifian G, Aseminia P, Heidary D, Esformes JI. Impact of creatine supplementation and exercise training in older adults: a systematic review and meta-analysis. Eur Rev Aging Phys Act. 2025;22(1). doi:10.1186/s11556-025-00384-9. Full text
• Liu S, Huang N, Wu W, et al. The impact of creatine supplementation associated with resistance training on muscular strength and lean tissue mass in the aged: a systematic review and meta-analysis. Eur Rev Aging Phys Act. 2025;22(1). doi:10.1186/s11556-025-00392-9. Full text
• Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14(1). doi:10.1186/s12970-017-0173-z. Full text

Tracking your own muscle, and what preservation looks like

• Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026;28(1):112-121. doi:10.1111/dom.70141. Full text
• Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. Sage Open Medical Case Reports. 2025;13. doi:10.1177/2050313x251388724. Full text

Drugs in development

• Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869-882. doi:10.1038/s41591-026-04204-0. Full text

Not indexed in the citation database, hand-composed per content-types.md §3

• University of Saskatchewan. A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy. ClinicalTrials.gov identifier NCT07625202. Recruiting; primary completion 30 May 2027. Accessed 30 July 2026. Registry record
• Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping. medRxiv 2026.04.11.26350687. Preprint, not peer reviewed.

This page has not yet been reviewed by a clinician. We write from the published evidence and say so when it is thin, but a named medical reviewer has not signed off on it. Talk to your prescriber about anything here that affects your own treatment.